-
TRANSPLANTATION: fibrinogen levels and bleeding before liver transplantation in end-stage liver disease: a cohort study
Time of Update: 2022-10-12
Preoperative Fibrinogen Level and Bleeding in Liver Transplantation for End-stage Liver Disease: A Cohort Study.
Preoperative Fibrinogen Level and Bleeding in Liver Transplantation for End-stage Liver Disease: A Cohort Study.
Preoperative Fibrinogen Level and Bleeding in Liver Transplantation for End-stage Liver Disease: A Cohort Study.
-
AJH: Anti-myeloma treatment outcomes after BCMA CAR-T for multiple myeloma still need to be improved
Time of Update: 2022-10-12
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
-
Clinical examination and evaluation of anemia
Time of Update: 2022-10-12
There are many items for anemia testing, the aim of identifying one of the two causes of anemia. One determination is anemia and its extent. The first of the two causes is what causes the patient's an
-
Heavy release! The 2021 "China Blood Research Expert Nomination List" was officially launched!!!!
Time of Update: 2022-10-12
Adhering to the principle of "objectivity and fairness", the event was selected and shortlisted for nearly 100 outstanding experts in the field of blood in China, and a total of 1 glorious pioneer list and 3 blood sub-professional lists were set up, which were divided into 2 honorary titles, "'Research' Value Peak Award" and "Outstanding Innovation Award".
-
Ther Adv Hematol: Infection is associated with myelodysplastic syndrome, chronic myeloid monocytic leukemia, and prognosis in patients with acute myeloid leukemia treated with hypomethylation drugs
Time of Update: 2022-10-12
The researchers obtained data from 412 unselected serial patients in 23 Spanish hospitals who were diagnosed with high-risk myelodysplastic syndrome, chronic monocytic leukemia or acute myeloid leukemia and received HMA treatment.
-
NEJM: GPRC5D-targeted CAR-T cell therapy for multiple myeloma treatment
Time of Update: 2022-10-12
In this Phase 1 dose-increasing study, we performed GPRC5D-targeted CAR T cell therapy (MCARH109) at four dose levels for patients with multiple myeloma who had undergone extensive pretreatment, including those who relapsed after BCMA CAR T cell therapy.
-
Application of Delarosx film-coated tablets in pediatric patients with transfusion-dependent thalassemia: a single-center experience
Time of Update: 2022-10-12
In terms of efficacy, the findings confirm that DFX FCT has a preventive effect on iron loading in the liver and heart, however, in order to ensure adequate chelation, higher doses are required than generally recommended.
-
Blood Adv: risk of thrombosis in adults with D-dimer and newly diagnosed acute lymphoblastic leukemia
Time of Update: 2022-10-12
They identified 61 consecutive adult patients with acute lymphoblastic leukemia, collected demographic features, treatment options, initial biomarkers (including D-dimers), and assessed the occurrence of venous or arterial thrombosis and bleeding in the first 100 days after diagnosis.
-
IMS 2022 Sneak Peek at the Progress of Bispecific Antibody Therapy in RRMM
Time of Update: 2022-10-06
1. Teclistamab Teclistamab, a BCMA × CD3 bispecific antibody, is being evaluated in the MajesTEC-1 study (single-arm, phase 1/2) for ≥3 lines of prior therapy (including immunomodulators, proteasome inhibitors, and anti-CD38 monotherapy) safety and efficacy in patients with anti) RRMM .
-
CSH Innovation Forum| Yan Jinsong, Zhao Xiangyu, Wang Liang, Wang Wenjing invite you to join the academic feast on September 23-25 - the 17th National Hematology Conference of the Chinese Medical Association
Time of Update: 2022-10-03
I sincerely hope that the content of this forum can help hematologists in many aspects such as the prevention, diagnosis, treatment and treatment of fungal infections, as well as the progress of treatment of new drugs!hematologic diseasesCell Therapy - From clinical research to normative application forumSeptember 23 8:30-12:00Professor Zhao XiangyuPeking University People's HospitalIt is a great pleasure to be the chair of the sub-forum on cell therapy – from basic research to standardized applications.
-
CSH Innovation Forum| Niu Ting, Yu Jia, Yan Xiaojing and Zhu Xiaoyu invite you to attend the 17th National Hematology Academic Conference of the Chinese Medical Association on September 23-25
Time of Update: 2022-10-03
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" will be grandly opened on Sep
-
Professor Ma Jun of World Lymphoma Day: Innovation continues to explore, lymphoma diagnosis and treatment has a long way to go, and the future can be expected
Time of Update: 2022-10-03
At the same time, Chemo-free, that is, the emergence of chemotherapy-free regimens, has also provided safer treatment options for more patients who cannot tolerate immunochemotherapy, which has significantly improved the survival of lymphoma patients and has become a malignant tumor with the highest clinical cure rate.
-
CSH Group Forum| Hu Yu, Hou Ming, Liu Qiqi, Zhao Weiying, Li Jianyong, Hu Xiaomei, Yang Tonghua, Xu Yang, Mei Heng invited you to review the National Hematology Conference of the Chinese Medical Association on September 23-25
Time of Update: 2022-10-03
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" will be grandly opened on Sep
-
A+ Academy Cloud Feast, big coffee hand in hand to talk about the frontiers of lymphoma treatment
Time of Update: 2022-10-03
With the aging of the population and the continuous improvement of the level of medical diagnosis, the incidence of lymphoma in China is also showing an upward trend, and lymphoma is gradually becomin
-
Qunyinghui No. 12 Literature Intensive Reading of a New Exploration of the Treatment of Invasive Lymphoma
Time of Update: 2022-10-03
Literature Intensive Reading (1)DLBCL treatment of new drugs, clinical treatment how to line up the army?Professor Li Jing shared an article published by the Journal of Hematology & Oncology entitled "New agents and regimens for diffuse large B cell lymphoma"[1].
-
The 2023 V1 CCCN CLL/SLL guidelines were updated with zebutinib becoming the only BTK inhibitor recommended by both the CSCO and NCCN guidelines as a double priority
Time of Update: 2022-10-03
v3 versionSwipe left and right to see moreTracing the source:The new generation of BTK inhibitor zebutinib recommended status improvedZebutinib is a new generation of structure-optimized BTKi independently developed in China, with more accurate target selectivity and lower off-target effect, thereby reducing the risk of adverse events such as atrial fibrillation, infection, rash, bleeding, etc.
-
Big coffee interview with Professor Zhou Hu: The diagnosis and treatment of MDS still faces many challenges, and "standardization" is the top priority
Time of Update: 2022-10-03
Medical Pulse Pass: Compared with lymphoma and leukemia, the progress of MDS treatment is relatively slow, can you please introduce what new drug progress in the MDS field is worth paying attention to in recent years?Professor Zhou HuAccording to the revised International Prognostic Scoring System (IPSS-R), which is currently more commonly used, MDS is divided into very low risk, low risk, medium risk, high risk and very high risk.
-
Professor Wu Depei and Professor Fu Rong: Looking forward to the innovative treatment of rare disease PNH, grasping the innovative context, and basing on the Chinese experience
Time of Update: 2022-10-03
Crovalimab, as a new generation of C5 complement inhibitors, debuted at the National Conference on Red Blood Cell Disease (Anemia), can you please talk about the clinical progress of Crovalimab in combination with relevant research and share the efforts of Chinese clinical researchers in this regard?Professor Fu RongThe publication of Crovalimab's clinical data offers hope for PNH treatment.
-
CSH Innovation Forum| Ji Chunyan, Li Jian, Qian Wenbin, Liu Peng, Li Xin invite you to join the academic feast on September 23-25 - the 17th National Hematology Academic Conference of the Chinese Medical Association
Time of Update: 2022-10-03
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" will be grandly opened on Sep
-
CSH Group Forum| Wu Depei, Chen Suning, Xiao Zhijian, Zhang Xiaohui, Zhang Liansheng, Fu Rong, Li Juan, Hou Jian invited you to attend the National Hematology Academic Conference of the Chinese Medical Association on September 23-25
Time of Update: 2022-10-03
Professor Suning Chen The First Affiliated Hospital of Soochow University Dear experts and colleagues, the 17th National Hematology Academic Conference of the Chinese Medical Association - Experimental Diagnostics Group Forum includes 12 special lectures and 17 speeches, covering all aspects of blood diseases, including morphology, immunology, cytogenetics, molecular diagnosis, etc.
